Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Behav Brain Res ; 343: 83-94, 2018 05 02.
Article in English | MEDLINE | ID: mdl-29410048

ABSTRACT

Dopamine reuptake inhibitors have been shown to improve cognitive parameters in various tasks and animal models. We recently reported a series of modafinil analogues, of which the most promising, 5-((benzhydrylsulfinyl)methyl) thiazole (CE-123), was selected for further development. The present study aims to characterize pharmacological properties of CE-123 and to investigate the potential to enhance memory performance in a rat model. In vitro transporter assays were performed in cells expressing human transporters. CE-123 blocked uptake of [3H] dopamine (IC50 = 4.606 µM) while effects on serotonin (SERT) and the norepinephrine transporter (NET) were negligible. Blood-brain barrier and pharmacokinetic studies showed that the compound reached the brain and lower elimination than R-modafinil. The Pro-cognitive effect was evaluated in a spatial hole-board task in male Sprague-Dawley rats and CE-123 enhances memory acquisition and memory retrieval, represented by significantly increased reference memory indices and shortened latency. Since DAT blockers can be considered as indirect dopamine receptor agonists, western blotting was used to quantify protein levels of dopamine receptors D1R, D2R and D5R and DAT in the synaptosomal fraction of hippocampal subregions CA1, CA3 and dentate gyrus (DG). CE-123 administration in rats increased total DAT levels and D1R protein levels were significantly increased in CA1 and CA3 in treated/trained groups. The increase of D5R was observed in DG only. Dopamine receptors, particularly D1R, seem to play a role in mediating CE-123-induced memory enhancement. Dopamine reuptake inhibition by CE-123 may represent a novel and improved stimulant therapeutic for impairments of cognitive functions.


Subject(s)
Benzhydryl Compounds/pharmacology , Dopamine Uptake Inhibitors/pharmacology , Learning/drug effects , Mental Recall/drug effects , Nootropic Agents/pharmacology , Spatial Memory/drug effects , Animals , Benzhydryl Compounds/chemistry , Benzhydryl Compounds/pharmacokinetics , Brain/drug effects , Brain/metabolism , Cell Line , Dopamine Uptake Inhibitors/chemistry , Dopamine Uptake Inhibitors/pharmacokinetics , Drug Evaluation, Preclinical , Humans , Male , Membrane Transport Proteins/metabolism , Mice , Modafinil , Molecular Docking Simulation , Molecular Structure , Motor Activity/drug effects , Nootropic Agents/chemistry , Nootropic Agents/pharmacokinetics , Rats, Sprague-Dawley , Receptors, Dopamine/metabolism
2.
Behav Brain Res ; 312: 127-37, 2016 10 01.
Article in English | MEDLINE | ID: mdl-27288589

ABSTRACT

A series of compounds targeting the dopamine transporter (DAT) haS been shown to improve memory performance most probably by re-uptake inhibition. Although specific DAT inhibitors are available, there is limited information about specificity, mechanism and in particular the effect on dopamine receptors. It was therefore the aim of the study to test the DAT inhibitor 4-(diphenyl-methanesulfinylmethyl)-2-methyl-thiazole (code: CE-111), synthetized in our laboratory for the specificity to target DAT, for the effects upon spatial memory and for induced dopamine receptor modulation. Re-uptake inhibition was tested for DAT (IC50=3.2µM), serotonin transporter, SERT (IC50=272291µM) and noradrenaline transporter, NET (IC50=174µM). Spatial memory was studied in the radial arm maze (RAM) in male Sprague-Dawley rats that were intraperitoneally injected with CE-111 (1 or 10mg/kg body weight). Performance in the RAM was improved using 1 and 10mg/kg body weight of CE-111. Training and treatment effects on presynaptic, postsynaptic and extrasynaptic D1 and D2- receptors and dopamine receptor containing complexes as well as on activated DAT were observed. CE-111 was crossing the blood-brain barrier comparable to modafinil and was identified as effective to improve memory performance in the RAM. Dopamine re-uptake inhibition along with modulations in dopamine receptors are proposed as potential underlying mechanisms.


Subject(s)
Benzhydryl Compounds/administration & dosage , Benzhydryl Compounds/pharmacology , Benzhydryl Compounds/pharmacokinetics , Dopamine Plasma Membrane Transport Proteins/metabolism , Dopamine Uptake Inhibitors/pharmacology , Heterocyclic Compounds/pharmacology , Maze Learning/drug effects , Receptors, Dopamine/metabolism , Thiazoles/administration & dosage , Thiazoles/pharmacology , Thiazoles/pharmacokinetics , Animals , Blood-Brain Barrier/metabolism , Dopamine/metabolism , Dopamine Uptake Inhibitors/chemical synthesis , HEK293 Cells , Heterocyclic Compounds/chemical synthesis , Hippocampus/cytology , Hippocampus/metabolism , Humans , Male , Pyramidal Cells/cytology , Pyramidal Cells/metabolism , RNA-Binding Proteins/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Dopamine D1/metabolism , Receptors, Dopamine D2/metabolism , Receptors, Dopamine D3/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...